论文部分内容阅读
长期用左旋多巴治疗的帕金森氏病患者中,50—80％最终将出现运动方面的并发症,包括与服药有关的运动症状波动和药物诱发的异常不随意运动,其发生机制与左旋多巴的外周药动学和中枢药动学的变化及中枢药效学的改变有关。PET已证实有波动反应的帕金森氏病患者中枢多巴胺受体位点减少。对这些并发症的治疗非常困难,有效的对策旨在早期合理用药及发现新的有效的治疗因子。
50-80% of patients with Parkinson’s disease who have been treated with levodopa for the long term will eventually experience motor complications including motor-related exercise-induced fluctuations and drug-induced abnormal involuntary movements that are associated with L-more Pakistan’s peripheral pharmacokinetics and central pharmacokinetic changes and changes in central pharmacodynamics. PET has been shown to fluctuate in Parkinson’s disease patients with reduced central dopamine receptor sites. The treatment of these complications is very difficult, effective measures aimed at early rational use of drugs and the discovery of new and effective treatment factors.